Get access

In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole

Authors

  • Shivaprakash M. Rudramurthy,

    1. Department of Medical Microbiology, Division of Mycology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
    Search for more papers by this author
  • Manu Jatana,

    Search for more papers by this author
    • Present address: Professor of Microbiology, Faculty of Biotechnology, Shoolini University, Bajhol, P.O. Sultanpur – 173 229, Distt Solan, Himachal Pradesh, India

  • Rachna Singh,

    1. Department of Medical Microbiology, Division of Mycology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
    Search for more papers by this author
  • Arunaloke Chakrabarti

    1. Department of Medical Microbiology, Division of Mycology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
    Search for more papers by this author

Dr A. Chakrabarti, MD, Dip NB, Professor and In-Charge, Department of Medical Microbiology, Division of Mycology, PGIMER, Chandigarh-160012, India.
Tel.: +91 172 2755156. Fax: +91 172 2747990.
E-mail: arunaloke@hotmail.com

Summary

FungisomeTM is a liposomal preparation of amphotericin B (AMB), already marketed in India. However, its antifungal activity has not been evaluated against a wide range of fungal pathogens. The study was planned to elucidate the in vitro antifungal activity of FungisomeTM against wide range of fungi and compare it with AMB deoxycholate (AMB-d), voriconazole (VOR), itraconazole (ITR) and fluconazole (FLU). Minimum inhibitory concentrations (MICs) of the drugs were determined for 262 clinical fungal isolates, including yeast, dimorphic and filamentous fungi, by broth microdilution method approved by Clinical and Laboratory Standards Institute, USA (yeast, M27-A3; filamentous fungi, M38-A2). The MIC90s of FungisomeTM were 0.125, 0.5 and 0.25 mg l−1 against yeast, filamentous and dimorphic fungi respectively. In comparison, MIC90s of AMB-d, FLU, ITR and VOR were 1, 1 and 1 mg l−1 (AMB-d), 4, 64 and 64 mg l−1 (FLU), 1, 16 and 16 mg l−1 (ITR) and 0.5, 4 and 16 mg l−1 (VOR) against yeast, filamentous and dimorphic fungi respectively. The MIC of FungisomeTM was two to 16-fold lower than AMB-d. These results reveal an efficient in vitro activity of FungisomeTM.

Ancillary